Claritev's Record Bookings and Guidance Raise Benchmark a Real 'Way Up' Inflection

The former MultiPlan posts its fifth straight growth quarter, blows past 2025 bookings in six months, and leans on NSA scale plus AI to defend its moat.

MPLN-WT · Earnings Call · 2026-08-07

Healthcare cost-management veteran Claritev — the 45-year-old business formerly known as MultiPlan — used its Q2 2026 print to put hard numbers behind a transformation narrative that has often been heavy on aspiration and light on delivery. Revenue of $257.5M rose 6.6% year-over-year, the fifth straight quarter of growth and the highest quarterly print in 15 quarters. Adjusted EBITDA of $155.8M at a 60.5% margin was the strongest absolute result in 13 quarters. But the more forward-looking signals live in the leading indicators: first-half bookings of $74M of ACV have already surpassed the $67M booked for all of 2025, average deal size is up more than 300% on an absolute-dollar basis, and 16 seven-figure ACV deals have closed year-to-date — up 25% versus last year. CEO Travis Dalton frames the quarter as the payoff of a deliberate two-year grind:

You are what your record says you are, and our results demonstrate that our strategy is working, our execution is strengthening, growth is returning, and we are building forward momentum across the business.
Travis Dalton, President and Chief Executive Officer · 2026-08-07

The Engine: NSA Volume and an AI-Ready Moat

The outperformance is not spread evenly — it's driven by the No Surprises Act (NSA) and independent dispute resolution (IDR) workflow, where Claritev claims genuine market leadership. CFO Doug Garis attributed the Claims Intelligence surge (up ~14% in the quarter) largely to a single large client win plus volume that pulled forward from Q1, and he flagged a structural tailwind from the finalized IDR rules, which cut the cost per dispute from $115 to $15. The arbitration win-rate advantage is stark: “We're performing 8 points better than the next closest compare.” — Doug Garis, Chief Financial Officer · 2026-08-07 That scale advantage is also the earnings growth story's moat. Claritev's position as the largest independent NSA/IDR processor outside the in-sourced payer giants means every regulatory complexity — the 27 state versions of surprise-bill rules, the new federal final rulings — funnels more workflow onto its platform. The macro backdrop (self-funded enrollment stable, out-of-network claims in the mid-7% range, medical inflation running 8-10%) provides durable demand. The AI angle is the differentiator worth watching. Management states it already runs dozens of production AI models and generates more than half its code with AI. The ProPricer tool claims to have identified over $1B of additional savings, and the IDR funnel itself is a natural AI target: “Our analysis indicates that nearly half of all IDR submissions are ineligible, highlighting a significant opportunity to use AI to improve efficiency and accelerate our clients' ability to respond quickly.” — Travis Dalton, President and Chief Executive Officer · 2026-08-07 This is commercial readiness in practice — data architecture modernized ahead of the AI wave, then monetized through faster, cheaper arbitration outcomes.

Bookings Breadth and the TPA Bet

A second unheralded signal is the breadth of bookings. The TPA vertical was the largest contributor to Q2 bookings, with several seven-figure deals including Marpai (which selected payment and revenue integrity for both prepaid and postpaid claims), plus a new Medicare Advantage network build (a high-six-figure ACV new logo). Doug Garis noted roughly a third of the $300M+ active pipeline sits in new verticals, with public-sector names like the World Trade Center deal representing a category the company "would have never bid on before." That diversification — future success in the making — is what turns a single-quarter beat into a multiyear re-rating case. Cross-sell/upsell still drove ~75% of bookings, but five new logos in the quarter (11 year-to-date) show the greenfield engine is lit. Management explicitly guided to "at least 50% ACV bookings growth for the year" and reiterated the $100M bookings aspiration.

Guidance, Cash Flow, and the Caveats

On the strength of Q2, Claritev raised full-year revenue guidance by two full percentage points to $1.00-1.02B (4-6% growth), raised adjusted EBITDA to $610-620M, and lifted free cash flow guidance to $5-15M. The cash-flow mechanics matter here: Q2 generated $93M of operating cash flow (up 51%), $89.5M of unlevered free cash flow, and $54.6M of levered free cash flow — the strongest in 15 quarters, up 49% year-over-year. Doug Garis was explicit about the conversion math this implies: “New bookings take on average 2 to 4 quarters to convert to revenue and then another 4 quarters to achieve fully annualized revenue contribution.” — Doug Garis, Chief Financial Officer · 2026-08-07 The caveats are real. This is a single-quarter re-rate with concentration risk — the NSA surge is largely one client, and network revenue faces an $18.5M onetime-comparison drag from last year. Management also models conservatively, guiding a "low single-digit" volume decline for the full year even after the sequential jump. The probability of success rests on whether the bookings engine can keep compounding against the 2-4 quarter revenue lag without fading into another transformation-year pause. For now, the record says the "year of the way up" is delivering a genuine operational inflection.